EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of epigenetically silenced tumour suppressor genes in aggressive breast cancer through a computational approach

Anne-Laure Vitte iD, Florent Chuffart iD, Emmanuelle Jacquet iD, Eleni Nika, Mireille Mousseau, Ina Jung iD, Séverine Tabone-Eglinger iD, Thomas Bachelot iD, Sophie Rousseaux iD, Saadi Khochbin iD, Ekaterina Bourova-Flin iD

NAR Cancer · 02.04.2025 · 7 (2)

DOI: 10.1093/narcan/zcaf020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NAR Cancer, online erschienen am 18.06.2025. Verfasst von Anne-Laure Vitte und 10 weiteren Autor:innen. Beteiligte Einrichtung: Université Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, 38000 Grenoble, France. Hauptthemen laut MEDLINE: Breast Neoplasms, GATA3 Transcription Factor, Epigenesis, Genetic, Genes, Tumor Suppressor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer ITMO, Association Espoir Isere contre le cancer, Groupement des Entreprises Françaises dans la Lutte contre le Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is characterized by genetic and epigenetic deregulations, leading to aberrant expression of tissue-specific genes that are normally silent in healthy breast tissue. Our previous work identified the embryonic stem cell-specific gene DNMT3B, a de novo DNA methyltransferase, as aberrantly activated in breast cancer, correlating with aggressive tumour behaviour and high relapse risk, regardless of molecular subtype. Through integrative bioinformatic analyses of DNA methylation and transcriptomic data, we identified 154 genes downregulated via DNMT3B-driven promoter hypermethylation, many of which are associated with high relapse risk. Notably, the tumour suppressor gene GATA3 emerged as a primary target of functional inactivation through either loss-of-function mutations or DNMT3B-controlled hypermethylation, in a mutually exclusive manner. Both mechanisms of GATA3 inactivation were associated with similar molecular signatures linked to tumour progression, increased malignancy, and poorer prognosis. However, distinct differences were observed, with immune- and inflammation-related genes enriched in GATA3 hypermethylation cases but depleted in mutation-driven silencing. Additionally, our analysis uncovered other potential tumour suppressor genes epigenetically repressed in aggressive breast cancers. These findings underscore a broader role of GATA3 inactivation beyond genetic alterations and suggest therapeutic opportunities to target epigenetically silenced tumour suppressors in aggressive breast tumours.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsGATA3 Transcription FactorEpigenesis, GeneticGenes, Tumor SuppressorGene SilencingDNA (Cytosine-5-)-MethyltransferasesHumansFemaleDNA MethylationGene Expression Regulation, NeoplasticDNA Methyltransferase 3BComputational BiologyPromoter Regions, Genetic

Substanzen

GATA3 Transcription FactorGATA3 protein, humanDNA Methyltransferase 3BDNA (Cytosine-5-)-Methyltransferases

Autor:innen und Institutionen

  • Université Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, 38000 Grenoble, France.
  • Medical Oncology Unit, Cancer and Blood Diseases Department, CHU Grenoble Alpes, CS 10217 - 38043 Grenoble cedex 09, France.
  • Department of Pathology, CHU Grenoble Alpes, CS 10217 - 38043 Grenoble cedex 09, France.
  • Plateforme de Gestion des Echantillons Biologiques, Centre Léon Bérard, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Lyon, France.
  • Department of Oncology, Centre Léon Bérard, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Lyon, France.

ORCID-Profile: Anne-Laure Vitte, Florent Chuffart, Emmanuelle Jacquet, Ina Jung, Séverine Tabone-Eglinger, Thomas Bachelot, Sophie Rousseaux, Saadi Khochbin, Ekaterina Bourova-Flin

Förderung

  • Cancer ITMO
  • Association Espoir Isere contre le cancer
  • Groupement des Entreprises Françaises dans la Lutte contre le Cancer
  • Plan Cancer Pitcher
  • MSD Avenir ERICAN
  • INCa-IreSP
  • Grenoble research communities

Zitieren

APA

Vitte, A. L., Chuffart, F., Jacquet, E., Nika, E., Mousseau, M., Jung, I., Tabone-Eglinger, S., Bachelot, T., Rousseaux, S., Khochbin, S., & Bourova-Flin, E. (2025). Discovery of epigenetically silenced tumour suppressor genes in aggressive breast cancer through a computational approach. NAR Cancer, 7(2). https://doi.org/10.1093/narcan/zcaf020

Vancouver

Vitte AL, Chuffart F, Jacquet E, Nika E, Mousseau M, Jung I, et al. Discovery of epigenetically silenced tumour suppressor genes in aggressive breast cancer through a computational approach. NAR Cancer. 2025;7(2). doi:10.1093/narcan/zcaf020

BibTeX
@article{Vitte2025,
  author = {Vitte, Anne-Laure and Chuffart, Florent and Jacquet, Emmanuelle and Nika, Eleni and Mousseau, Mireille and Jung, Ina and Tabone-Eglinger, Séverine and Bachelot, Thomas and Rousseaux, Sophie and Khochbin, Saadi and Bourova-Flin, Ekaterina},
  title = {Discovery of epigenetically silenced tumour suppressor genes in aggressive breast cancer through a computational approach},
  journal = {NAR Cancer},
  year = {2025},
  volume = {7},
  number = {2},
  doi = {10.1093/narcan/zcaf020}
}
Kostenlos starten →